Drug metabolism in human liver microsomes assessed as (Z)-6-(5-(5-carbamimidoylpyridin-2-yl)furan-2-yl)-N'-hydroxynicotinimidamide formation treated at 10 uM after 180 mins incubation by HPLC-UV chromatogram relative to initial prodrug concentration
Drug metabolism in rat liver microsomes assessed as (Z)-6-(5-(5-carbamimidoylpyridin-2-yl)furan-2-yl)-N'-hydroxynicotinimidamide formation treated at 10 uM after 180 mins incubation by HPLC-UV chromatogram relative to initial prodrug concentration
Prodrug conversion in human liver microsomes assessed as DB829 compound formation treated at 10 uM after 180 mins incubation by HPLC-UV chromatography relative to initial prodrug concentration
Prodrug conversion assessed as human recombinant CYP1A2-mediated (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl) nicotinimidamide formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as human recombinant CYP3A4-mediated (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl) nicotinimidamide formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as human recombinant CYP4F2-mediated (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl) nicotinimidamide formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as human recombinant CYP1A2-mediated (3Z,3'Z)-6,6'-(furan-2,5-diyl)bis(N'-hydroxynicotinimidamide) formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as rat recombinant CYP1A2-mediated (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl) nicotinimidamide formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as rat recombinant CYP2D2-mediated (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl) nicotinimidamide formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as rat recombinant CYP4F1-mediated (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl) nicotinimidamide formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Prodrug conversion assessed as rat recombinant CYP1A2-mediated (3Z,3'Z)-6,6'-(furan-2,5-diyl)bis(N'-hydroxynicotinimidamide) formation at 5 uM after 180 mins incubation by HPLC-UV chromatogram
Drug metabolism in rat recombinant CYP2C13 assessed as (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl nicotinimidamide formation treated with DB868
Drug metabolism in rat recombinant CYP2D1 assessed as (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl nicotinimidamide formation treated with DB868
Drug metabolism in human recombinant CYP2E1 assessed as (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl nicotinimidamide formation treated with DB868
Drug metabolism in rat recombinant CYP2E1 assessed as (Z)-N'-hydroxy-6-(5-(5-((Z)-N'-methoxycarbamimidoyl)pyridin-2-yl)furan-2-yl nicotinimidamide formation treated with DB868